TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01435109

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Behavioral Intervention for OA
Description: Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Intervention for OA
Description: Primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Patient and Provider Interventions for OA
Description: Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management; primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
Study: NCT04797793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene Gel 0.1%
Description: The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Differin® Gel (Adapalene 0.1%, Galderma)
Description: The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
Study: NCT01748643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deep neuromuscular blockade with rocuronium, reversal with sugammadex
Description: after induction of anesthesia, a rocuronium infusion (0.6mg/kg (lean body mass)/h,) is started and titrated to a post tetanic count of 1-2 twitches. At the end of surgery neuromuscular blockade will be reversed with sugammadex 4mg/kg. Patients are extubated when TOF ratio \> 0.9.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal neuromuscular blockade reversal with rocuronium, reversal with neostigmine
Description: After induction of anesthesia, top-ups of rocuronium (10mg) are given as needed to maintain a train of four count of 1-2. At the end of surgery neuromuscular blockade will be reversed with neostigmine 50μg/kg and glycopyrrolate 10μg/kg (lean body mass). Patients are extubated when the train of four ratio is \> 0.9.
Study: NCT03954951

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multimodality behavioral strategy
Description: * On-line course on hypertension management based on the new ACC/AHA and ESC/ESH guidelines on hypertension management.~* Weekly performance feedback reports: will include percent of patients with uncontrolled hypertension and among this group percent of visits where no change in medication was made. It will also include a comparative assessment of the performance of the physicians compared with their colleagues in the province.
Study: NCT01341964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: 600mg (2 pills)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 600mg (2 pills)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 325mg (1 pill)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 81mg (1 pill)
Study: NCT03141242

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ENACT group visit
Description: Participation in two 2 hour group visits about advance care planning.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mailed Resources
Description: Participants will receive advance care planning resources in the mail with instructions to follow up with their primary care provider.
Study: NCT01673451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2006
Description: Part A: 2.5 mg, 5 mg, 10 mg, 25 mg, 50 mg, and 75 mg E2006 administered as capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: E2006-matched placebo (Part A and Part B); Part B: dose level to be determined based on results of Part A, administered as capsules
Study: NCT02409459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injectafer

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline solution
Study: NCT00778089

Intervention type: DEVICE
Group type: OTHER
Intervention: ArteFill® Skin Test
Description: Subjects will receive the ArteFill® Skin Test at Visit 1, Day 0 on the volar forearm. After 30 days, if the test result is negative a second skin test will be administered on the contra volar forearm at Visit, 3, Day 30.
Study: NCT01904682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral rigosertib
Description: Dose of 560 mg consists of two (2) 280 mg soft gel capsules of rigosertib.
Study: NCT03641144

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Navigation laser
Description: Navigation laser device is a scanning slit-based instrument.before treatment the surgeon plan laser spots on the screen based on image(infrared, colour, fluorescein angiography)and then apply automated patterns and single spots as appropriate.the device will automatically carry out the plan.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional laser
Description: Traditional laser is a slitlamp based instrument.Surgeon operate traditional laer device while watching Participant's image(infrared, colour, fluorescein angiography) and then manually aim at and trigger laser.
Study: NCT01966640

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Basophil Activation Test
Description: blood sample for Basophil Activation Test
Study: NCT02771158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine
Description: midodrine is metabolized to an active metabolite, desglymidodrine, which is an alpha adrenergic antagonist that causes vasoconstriction of both venous and arterial vasculature, thereby increasing blood pressure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo will be administered to double blind the study
Study: NCT02502539

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Controlled physical activity
Study: NCT01768481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 10 mg Atorvastatin vs placebo daily in a randomized controlled trial for one year

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: placebo controlled arm receives similarly looking placebo.
Study: NCT00827970

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screening for urogenital Chlamydia trachomatis
Description: Receeiving an invitation to be tested for urogenital Chlamydia trachomatis by use of a home-obtained and mailed sample.
Study: NCT03610022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with vismodegib
Description: Vismodegib 150 mg capsules is administered daily with or without food until disease progression or unacceptable toxicity. Patients are followed in the dermatologic unit of Bordeaux University Hospital (Saint André Hospital) every month. At each consultation, clinical and biological datas, and two blood samples are collected just before taking the drug. One sample is for vismodegib quantification (pharmacokinetic protocol), and the other for the determination of alpha-1 glycoprotein acid level
Study: NCT05641233

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy
Description: Preoperative radiotherapy delivered in a single fraction of 12 Gy focussed on 4cm pancreas at the intended (i.e. future) anastomotic site.
Study: NCT01172184

Intervention type: PROCEDURE
Intervention: Cardiac catheterization
Description: Before surgical intervention for severe mitral regurgitation, cardiac catheterization will be performed and left ventricular filling pressure will be assessed. Simultaneously, echocardiography, including left atrial distensibility, will be performed.
Study: NCT01042327

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELISIO dialyzer
Description: 3 x week dialysis using ELISIO dialyzer for 12 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fresenius FX100 dialyzer
Study: NCT00128778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin
Study: NCT00643032

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous iliohypogastric

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Perioperative administration near the nerve
Study: NCT04567433

Intervention type: DRUG
Intervention: Hydroxyethyl starch
Description: Hydroxyethyl starch compared to 0.9% saline

Intervention type: DRUG
Intervention: Hydrocortisone
Description: Hydrocortisone compared to Placebo

Intervention type: PROCEDURE
Intervention: Early Goal Directed Therapy
Description: Early Goal Directed Therapy compared to Usual Care
Study: NCT03007381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine
Description: Intravenous analgesic

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal Saline
Description: Sham comparator
Study: NCT03051607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tozadenant
Description: 1 Year Open Label, 120 mg BID tozadenant, with dose modification to 60 mg BID tozadenant permitted.
Study: NCT02567942

Intervention type: DRUG
Group type: OTHER
Intervention: propofol group
Description: Patient will be anesthetized by using propofol infusion during operation

Intervention type: DRUG
Group type: OTHER
Intervention: sevoflurane group
Description: Patient will be anesthetized by using sevoflurane inhalation during operation
Study: NCT03946384

Intervention type: OTHER
Intervention: data collection
Description: data collection on the history of the disease, hemophilia
Study: NCT05467436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local anesthetics, IV sedation drugs and analgesics.
Description: Personalized prescription for local anesthetics, IV sedation drugs and analgesics, based on pharmacogenomic assesment, social, dietary and medication history
Study: NCT02062879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine administered as patient-controlled analgesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: Hydromorphone administered as patient-controlled analgesia.
Study: NCT05713045

Intervention type: DIETARY_SUPPLEMENT
Intervention: Konakion
Description: Comparing 4 different regimen of Vitamin K administration in newborn

Intervention type: DIETARY_SUPPLEMENT
Intervention: Konakion
Description: Comparing 4 different regimen of Vitamin K administration in newborn

Intervention type: DIETARY_SUPPLEMENT
Intervention: Konakion
Description: Comparing 4 different regimen of Vitamin K administration in newborn

Intervention type: DIETARY_SUPPLEMENT
Intervention: Konakion
Description: Comparing 4 different regimen of Vitamin K administration in newborn
Study: NCT02314650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupoint stimulation
Description: stimulation was given at acupoints

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: non-acupoint stimulation
Description: stimulation was given at non-acupoints

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: electrodes attached
Description: electrode were attached to skin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: electrodes attached
Description: electrode were attached to skin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrodes attached
Description: electrode were attached to skin
Study: NCT01067014

Intervention type: DEVICE
Intervention: Baxano iO-Flex® System
Description: Decompressive lumbar surgery using Baxano iO-Flex® System
Study: NCT03755687

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Art Therapy Intervention
Description: Standardized mixed media art directives.
Study: NCT05603689

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isocaloric ketogenic diet
Description: The ICKD definition was based on the works of Sansone (2018) and Trimboli (2020). We defined ICKD as a daily CHOs ingestion \< 30 to 50 g.d-1, without any limitation in fat consumption. Participants self-selected their own diet based on a list of advised and forbidden foods developed to fit the definition of ICKD. There were no instructions to limit calories.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Isocaloric ketogenic diet
Description: The ICKD definition was based on the works of Sansone (2018) and Trimboli (2020). We defined ICKD as a daily CHOs ingestion \< 30 to 50 g.d-1, without any limitation in fat consumption. Participants self-selected their own diet based on a list of advised and forbidden foods developed to fit the definition of ICKD. There were no instructions to limit calories.
Study: NCT03510520

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medium Cut-Off Haemodialysis
Description: Treatment with medium cut-off haemodialysis using the Theranova dialysis membrane 3 times per week for 6 months

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: On-Line Haemodiafiltration
Description: Treatment with on-line haemodiafiltration (HDF) 3 times per week for 6 months (Conventional treatment)
Study: NCT02286505

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain Morphometry
Description: Quantitative, automated reading of hippocampal volume from MRI scans, complemented by a general measure of brain atrophy, in addition to standard neuroradiological report.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard radiological assessment
Description: Standard neuroradiological report produced by qualitative examination of structural MRI scan by trained neuroradiologist.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard radiological assessment
Description: Standard neuroradiological report produced by qualitative examination of structural MRI scan by trained neuroradiologist.
Study: NCT01969877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Study: NCT00651326

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: 46 Gy in 23 fractions over \< 5 weeks.~Boost:~24-28 Gy in 12-14 fractions over \< 3 weeks

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: 46 Gy in 23 fractions over \< 5 weeks.~Boost:~24-28 Gy in 12-14 fractions over \< 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Study: NCT03788811

Intervention type: DEVICE
Intervention: ERG assessment (RSPA)
Description: Processing and analysis of retinal signals
Study: NCT01969877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Study: NCT02008981

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin (enteric-coated) at 100mg daily will be given one of the actual herb or placebo herb, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
Study: NCT00130221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate impregnated cloth

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Daily bathing with Bar soap
Description: bathed daily with bar soap (Dial Corp., Scottsdale, AZ), warm water, and cotton washcloths.
Study: NCT02008981

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin (enteric-coated) at 100mg daily will be given one of the actual herb or placebo herb, each for a 3 week period. Clotting profile and platelet function test will be done before and after.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin (enteric-coated) at 100mg daily will be given one of the actual herb or placebo herb, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
Study: NCT03459963

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: indwelling urinary catheter
Description: 85 women undergoing first elective CS will be catheterized immediately preoperatively using Foley's catheter by applying catheterization precautions.
Study: NCT01969877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study: NCT05158985

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: phonophoresis
Description: treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: phonophoresis
Description: treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: phonophoresis
Description: treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercises
Description: treatment
Study: NCT04515368

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunization
Description: Immunisation with one of four licensed vaccines

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunization
Description: Immunisation with one of four licensed vaccines

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunization
Description: Immunisation with one of four licensed vaccines

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunization
Description: Immunisation with one of four licensed vaccines
Study: NCT03964753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel and Cisplatin
Description: Nab-paclitaxel,125mg/m(2), d1,d8, Cisplatin,75mg/m(2), d1, 3 week, 2 cycles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: surgery
Study: NCT02713529

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG820 and pembrolizumab
Description: Treatment with AMG820 and pembrolizumab
Study: NCT00068510

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous dendritic cells
Study: NCT04297969

Intervention type: DIAGNOSTIC_TEST
Intervention: objective pediatric vision screen GCK glow fixation
Description: 2-axis, smart phone flash concentrated photoscreen using novel, low-detail, color glow fixation device
Study: NCT02225912

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PrevinC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02644902

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Avatar assisted cascade training
Description: Training of health workers in THP through tablets including avatar characters , and cascaded supervision model.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Specialist led training in THP
Description: Training and supervision of lady health workers by specialists as in original THP
Study: NCT03512431

Intervention type: DIAGNOSTIC_TEST
Intervention: Micro sampling
Description: Compare finger prick micro samples with venous blood samples for measuring whole blood tacrolimus concentrations
Study: NCT01213823

Intervention type: OTHER
Intervention: Does not apply
Description: This is a non-interventional study, therefore the intervention type / name do not apply

Intervention type: OTHER
Intervention: Does not apply
Description: This is a non-interventional study, therefore the intervention type / name do not apply
Study: NCT02001896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine; cisplatin or carboplatin; erlotinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib
Study: NCT00595933

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sugar-free chewing gum
Description: Chew gum 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chewing gum
Description: Chew gum 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mouth rinse
Description: Rinse mouth 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week questionaire

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mouth rinse
Description: Rinse mouth 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mouth spray
Description: Spray mouth with mouth spray 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mouth spray
Description: Spray mouth 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week
Study: NCT00993733

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous veno-venous haemodiafiltration
Description: Dialysis procedure administrated to the patients with acute renal failure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous veno-venous haemodiafiltration
Description: Dialysis procedure administrated to the patients with acute renal failure
Study: NCT03627169

Intervention type: DEVICE
Intervention: MATRx plus
Description: The MATRx plus device will be used in its capacity as a Level III home sleep apnea test (HSAT). Note: MATRx plus is approved for use in Canada; therefore, the study does not involve any investigational devices.
Study: NCT00420173

Intervention type: PROCEDURE
Intervention: Laboratory analysis
Description: blood withdrawal
Study: NCT01680627

Intervention type: BEHAVIORAL
Intervention: CASI
Study: NCT00797680

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 72 hours hypothermia
Description: 72 hours mild hypothermia (33 +/1 1 degree Celsius)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 24 hours hypothermia
Description: 24 hours mild hypothermia (33 +/1 1 degree Celsius)
Study: NCT04965961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPO
Description: Please refer to the arm description

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group - saline injection
Description: Please refer to the arm description